Network meta-analysis of SGLT-2 inhibitor-induced hypoglycemia risk in type 2 diabetes patients

ZHUO Jun; LING Juan; JIANG Yan; LI Ting; WANG Jie

doi:10.6039/j.issn.1001-0408.2023.12.19

您当前的位置：

首页 >

文章列表页 >

Network meta-analysis of SGLT-2 inhibitor-induced hypoglycemia risk in type 2 diabetes patients

更新时间：2023-06-26

- Network meta-analysis of SGLT-2 inhibitor-induced hypoglycemia risk in type 2 diabetes patients
- ZHONGGUO YAOFANG Vol. 34, Issue 12, Pages: 1509-1514(2023)
- 作者机构：
  
  1.甘肃省中医院临床药学科，兰州　730050
  2.甘肃省人民医院感染管理科，兰州　730030
  3.甘肃中医药大学第一临床医学院，兰州　730030
  4.陕西中医药大学附属医院药剂科，咸阳　712000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.12.19
  CLC： R977.1+5
- Published：30 June 2023，
  
  Received：09 January 2023，
  
  Revised：26 May 2023，
扫描看全文
禚君,令娟,江燕等.SGLT-2抑制剂致2型糖尿病患者低血糖的网状Meta分析 ^Δ[J].中国药房,2023,34(12):1509-1514.

ZHUO Jun,LING Juan,JIANG Yan,et al.Network meta-analysis of SGLT-2 inhibitor-induced hypoglycemia risk in type 2 diabetes patients[J].ZHONGGUO YAOFANG,2023,34(12):1509-1514.
禚君,令娟,江燕等.SGLT-2抑制剂致2型糖尿病患者低血糖的网状Meta分析 ^Δ[J].中国药房,2023,34(12):1509-1514. DOI： 10.6039/j.issn.1001-0408.2023.12.19.

ZHUO Jun,LING Juan,JIANG Yan,et al.Network meta-analysis of SGLT-2 inhibitor-induced hypoglycemia risk in type 2 diabetes patients[J].ZHONGGUO YAOFANG,2023,34(12):1509-1514. DOI： 10.6039/j.issn.1001-0408.2023.12.19.

摘要

目的

评价钠-葡萄糖共转运蛋白2（SGLT-2）抑制剂致2型糖尿病（T2DM）患者低血糖的发生风险。

方法

计算机检索PubMed、Web of Science、Cochrane图书馆、中国知网、维普网、万方数据、中国生物医学文献数据库，收集SGLT-2抑制剂治疗T2DM的随机对照试验（RCT），检索时限均为建库起至2022年10月15日。筛选文献、提取数据，采用Cochrane系统评价员手册推荐的5.1.0 偏倚风险评估工具对纳入文献进行质量评价后，采用Stata 15.1软件进行网状Meta分析和发表偏倚分析。

结果

共纳入22项RCT，共计18 734例患者。 Meta分析结果显示，与埃格列净15 mg[RR＝3.26，95%CI（1.13，8.11），

＜0.05]及埃格列净25 mg[RR＝3.08，95%CI（1.12，6.34），

＜0.05]比较，使用卡格列净300 mg时患者的低血糖发生率显著升高；与埃格列净15 mg[RR＝1.48，95%CI（1.24，6.93），

＜0.05]及埃格列净25 mg[RR＝6.74，95%CI（1.33，9.34），

＜0.05]比较，使用卡格列净100 mg时患者的低血糖发生率显著升高；其他各组间比较，差异均无统计学意义（

＞0.05）。网状Meta分析排序结果显示，低血糖发生率从低到高依次为：埃格列净15 mg＞安慰剂＞埃格列净25 mg＞恩格列净25 mg＞恩格列净10 mg＞恩格列净1 mg＞达格列净5 mg＞达格列净10 mg＞达格列净2.5 mg＞卡格列净300 mg＞埃格列净10 mg＞埃格列净5 mg＞恩格列净50 mg＞卡格列净200 mg＞卡格列净100 mg＞卡格列净50 mg＞埃格列净1 mg＞恩格列净5 mg。发表偏倚分析结果显示，本研究存在发表偏倚的可能性较小。

结论

SGLT-2抑制剂治疗T2DM时，以使用埃格列净15 mg低血糖发生率最低，使用恩格列净5 mg最高。

Abstract

OBJECTIVE

To evaluate the risk of hypoglycemia caused by sodium-glucose co-transporter protein 2 （SGLT-2） inhibitors in type 2 diabetes （T2DM） patients.

METHODS

Retrieved from PubMed， Web of Science， Cochrane Library， CNKI， VIP， Wanfang Data and CBM， randomized controlled trials （RCTs） about SGLT-2 inhibitors in the treatment of T2DM were collected from the inception to Oct. 15th， 2022. After literature screening， data extraction and quality evaluation of included literature with bias risk assessment tool recommended by the Cochrane system evaluator handbook 5.1.0， Stata 15.1 software was used for network meta-analysis and publication bias analysis.

RESULTS

A total of 22 RCTs were included， with a total of 18 734 patients. The results of meta-analysis showed that compared with ertugliflozin 15 mg [RR＝3.26， 95%CI （1.13， 8.11），

＜0.05] and ertugliflozin 25 mg [RR＝3.08， 95%CI （1.12， 6.34），

＜0.05]， the incidence of hypoglycemia was significantly increased in patients using canagliflozin 300 mg. Compared with ertugliflozin 15 mg [RR＝1.48， 95%CI （1.24， 6.93），

＜0.05] and ertugliflozin 25 mg [RR＝6.74， 95%CI （1.33， 9.34），

＜0.05]， the incidence of hypoglycemia in patients treated with canagliflozin 100 mg was significantly increased. There was no statistically significant difference between other groups （

＞0.05）. The ranking results of the network meta-analysis showed that the incidence of hypoglycemia was from low to high， ie. ertugliflozin 15 mg＞placebo＞ertugliflozin 25 mg＞empgaliflozin 25 mg＞empgaliflozin 10 mg＞empgaliflozin 1 mg＞dapagliflozin 5 mg＞dapagliflozin 10 mg＞dapagliflozin 2.5 mg＞canagliflozin 300 mg＞ertugliflozin 10 mg＞ertugliflozin 5 mg＞empgaliflozin 50 mg＞canagliflozin 200 mg＞canagliflozin 100 mg＞canag-liflozin 50 mg＞ertugliflozin 1 mg＞empgaliflozin 5 mg. Results of publication bias analysis showed that there was little possibility of publication bias in this study.

CONCLUSIONS

When SGLT-2 inhibitors are used in patients with T2DM， the incidence of hypoglycemia is the lowest when using ertugliflozin 15 mg， and the incidence of hypoglycemia is the highest when using empagliflozin 5 mg.

关键词

钠-葡萄糖共转运蛋白2抑制剂低血糖2型糖尿病网状Meta分析

Keywords

hypoglycemiatype 2 diabetesnetwork meta-analysis

references

VIVIAN E M. Sodium-glucose co-transporter 2（SGLT2）inhibitors：a growing class of antidiabetic agents[J]. Drugs Context，2014，3：212264.

HASAN F M，ALSAHLI M，GERICH J E. SGLT2 inhibitors in the treatment of type 2 diabetes[J]. Diabetes Res Clin Pract，2014，104（3）：297-322.

SCHEEN A J. Pharmacodynamics，efficacy and safety of sodium-glucose co-transporter type 2（SGLT2）inhibitors for the treatment of type 2 diabetes mellitus[J]. Drugs，2015，75（1）：33-59.

QIU H Y，NOVIKOV A，VALLON V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors：basic mechanisms and therapeutic perspectives[J]. Diabetes/metabolism Res Rev，2017，33（5）：1-9.

徐爱花，黄建胜，何银辉，等. 达格列净片治疗2型糖尿病血糖控制不佳患者的疗效与低血糖风险观察[J]. 中华全科医学，2020，18（9）：1500-1503，1526.

陈利敏，张立，刘俊伟. 恩格列净联合二甲双胍治疗2型糖尿病的效果及对低血糖发生率的影响[J]. 中国实用医刊，2022，49（13）：102-105.

郭秀梅，季德斌. 恩格列净联合二甲双胍对2型糖尿病患者血糖水平及低血糖风险的影响[J]. 吉林医学，2021，42（11）：2577-2579.

高文娟，李朋梅，赵莉. 2型糖尿病住院患者恩格列净不良反应发生情况分析[J]. 药物不良反应杂志，2021，23（6）：293-297.

中华医学会内分泌学分会. 中国糖尿病患者低血糖管理的专家共识[J]. 中华内分泌代谢杂志，2012，28（8）：619-623.

HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ， 2011，343：d5928.

SALANTI G，ADES A E，IOANNIDIS J P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis：an overview and tutorial[J]. J Clin Epidemiol，2011，64（2）：163-171.

BAILEY C J，GROSS J L，PIETERS A，et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin：a randomised，double-blind，placebo-controlled trial[J]. Lancet，2010，375（9733）：2223-2233.

STROJEK K，YOON K H，HRUBA V，et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride：a rando-mized，24-week，double-blind，placebo-controlled trial[J]. Diabetes Obes Metab，2011，13（10）：928-938.

WILDING J P H，CHARPENTIER G，HOLLANDER P，et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea：a randomised trial[J]. Int J Clin Pract，2013，67（12）：1267-1282.

KOVACS C S，SESHIAH V，SWALLOW R，et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes：a 24-week，rando-mized，placebo-controlled trial[J]. Diabetes Obes Metab，2014，16（2）：147-158.

ROSENSTOCK J，JELASKA A，FRAPPIN G，et al. Improved glucose control with weight loss，lower insulin doses，and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes[J]. Diabetes Care，2014，37（7）：1815-1823.

STROJEK K，YOON K H，HRUBA V，et al. Da-pagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks：a randomized，double-blind，parallel-group，placebo-controlled trial[J]. Diabetes Ther，2014，5（1）：267-283.

WILDING J P，WOO V，ROHWEDDER K，et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin：efficacy and safety over 2 years[J]. Diabetes Obes Metab，2014，16（2）：124-136.

AMIN N B，WANG X，JAIN S M，et al. Dose-ranging efficacy and safety study of ertugliflozin，a sodium-glucose co-transporter 2 inhibitor，in patients with type 2 diabetes on a background of metformin[J]. Diabetes Obes Metab，2015，17（6）：591-598.

BAILEY C J，MORALES VILLEGAS E C，WOO V，et al. Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes：a randomized double-blind placebo-controlled 102-week trial[J]. Diabet Med，2015，32（4）：531-541.

KOSIBOROD M，GAUSE-NILSSON I，XU J，et al. Ef-ficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure[J]. J Diabetes Complications，2017，31（7）：1215-1221.

WEBER M A，MANSFIELD T A，CAIN V A，et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy：a randomised，double-blind，placebo-controlled，phase 3 study[J]. Lancet Diabetes Endocrinol，2016，4（3）：211-220.

YANG W Y，HAN P，MIN K W，et al. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure：a randomized controlled trial[J]. J Diabetes，2016，8（6）：796-808.

YALE J F，XIE J，SHERMAN S E，et al.Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks：a randomized，controlled trial in patients with type 2 diabetes mellitus[J]. Clin Ther，2017，39（11）：2230-2242.e2.

INAGAKI N，HARASHIMA S I，KAKU K，et al. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab，2018，20（4）：812-820.

JI L N，LIU Y M，MIAO H，et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy：VERTIS Asia[J]. Diabetes Obes Metab，2019，21（6）：1474-1482.

CANNON C P，PRATLEY R，DAGOGO-JACK S，et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med，2020，383（15）：1425-1435.

PETRIE M C，VERMA S，DOCHERTY K F，et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes[J]. JAMA，2020，323（14）：1353-1368.

ARAKI E，MATHIEU C，SHIRAIWA T，et al. Long-term（52-week）efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes：subgroup analysis of the DEPICT-2 study[J]. Diabetes Obes Metab，2021，23（7）：1496-1504.

LIU J，TARASENKO L，PONG A，et al. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus[J]. Curr Med Res Opin，2020，36（7）：1097-1106.

LIU J，PATEL S，CATER N B，et al. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab，2020，22（4）：574-582.

INAGAKI N，KONDO K，YOSHINARI T，et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes：a randomized，double-blind，placebo-controlled，12-week study[J]. Diabetes Obes Metab，2013，15（12）：1136-1145.

ROSENSTOCK J，SEMAN L J，JELASKA A，et al. Efficacy and safety of empagliflozin，a sodium glucose cotransporter 2（SGLT2）inhibitor，as add-on to metformin in type 2 diabetes with mild hyperglycaemia[J]. Diabetes Obes Metab，2013，15（12）：1154-1160.

中华医学会糖尿病学分会，国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理指南：2018[J]. 中华内科杂志，2018，57（12）：885-893.

中华医学会糖尿病学分会. 中国2型糖尿病防治指南：2017年版[J]. 中国实用内科杂志，2018，38（4）：292-344.

陈铮. 降糖药物超临界点使用可引发低血糖和继发性失效[J]. 首都医药，2007，14（21）：49-51.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Network meta-analysis of triple therapy for the prevention and treatment of acute nausea and vomiting caused by emetogenic chemotherapy drugs with moderate and high risk

Pharmacotherapy plan for metastatic hormone-sensitive prostate cancer：a network meta-analysis

Network meta-analysis of the efficacy and safety of different drug regimens in the treatment of children with Kawasaki disease

Efficacy and safety of 4 kinds of hemocoagulases combined with proton pump inhibitor for nonvariceal upper gastrointestinal bleeding：a network meta-analysis

Efficacy and safety of five monoclonal antibodies in preventing relapse of neuromyelitis optica spectrum disorders： network meta-analysis

Related Author

JIN Pengfei

WANG Yang

ZHANG Yatong

LI Ting

ZHANG Tian

CHEN Wanyi

TANG Zongwei

SONG Haichi

Related Institution

Dept. of Pharmacy， Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine， Chinese Academy of Medical Sciences/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application （Beijing Hospital）

Dept. of Pharmacy， Chongqing University Cancer Hospital

Dept. of Pediatrics， Shunde Hospital of Southern Medical University （Shunde District First People’s Hospital of Foshan）

Dept. of Cardiovascular Medicine， Shunde Hospital of Southern Medical University （Shunde District First People’s Hospital of Foshan）

Dept. of Pharmacy， People’s Hospital of Peking University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰